• metastatic/advanced - esophageal cancer (mEC)
• mEC - (neo)adjuvant (NA) 1
• mEC - 1st line (L1) 1
• mEC - 2nd line (L2) 3
• gastric or gastroesophageal junction cancer (GC)

 

• antibody–drug conjugate
• trastuzumab deruxtecan
• immune chekpoint inhibitors
• anti-CTLA-4
• ipilimumab based treatment
• ipilimumab alone
• Ipilimumab (10 mg/kg)
• anti-PD-(L)1
• avelumab based treatment
• avelumab alone
• nivolumab based treatment
• nivolumab alone
• nivolumab plus SoC
• pembrolizumab based treatment
• pembrolizumab alone
• pembrolizumab plus SoC
• Immune checkpoint association
• durvalumab plus tremelimumab
• nivolumab plus ipilimumab

• versus all
• vs chemotherapy
• vs non platinum-based chemotherapy
• vs taxanes
• vs paclitaxel
• vs Standard of Care (SoC)
• vs placebo plus SoC
• vs immune chekpoint inhibitors
• vs anti-PD-(L)1
• vs durvalumab based treatment
• vs durvalumab alone
• vs nivolumab based treatment
• vs nivolumab alone
• vs non active control
• vs placebo

• study list
• mapping
• overview
• meta-analysis
• forest plot
• NMA
• excluded

Top evidence (RCT only, high risk of bias excluded) Best available evidence (possibly low or very low) All RCTs All studies (RCT+OBS)